人乳头瘤病毒相关的口咽鳞状细胞癌分子病理诊断新进展

doi:10.3969/j.issn.1004-616x.2022.02.015

摘要/Abstract

摘要： 人乳头瘤病毒(HPV)相关的感染与口咽鳞状细胞癌(OPSCC)的发生密切相关。基于HPV感染状态，WHO头颈部肿瘤分类2017版将OPSCC分为HPV阳性及HPV阴性两个类型。美国癌症联合委员会(AJCC)第8版癌症分期手册中建议将HPV的表达情况作为OPSCCs分级分期的重要指标之一。因此，HPV感染状态的判断成为OPSCC病理诊断的重要内容。本综述将重点阐述HPV相关OPSCC的组织形态学特点及HPV感染状态的检测方法，关注各种检测方法的优缺点，强调p16免疫组织化学联合HPV病毒特异性检测在OPSCC诊疗中的重要作用。

关键词: 口咽鳞状细胞癌, HPV, E6/E7 mRNA, p16, DNA

中图分类号:

R730.4

杨欣, 郭会芹. 人乳头瘤病毒相关的口咽鳞状细胞癌分子病理诊断新进展[J]. 癌变·畸变·突变, 2022, 34(2): 154-157.

参考文献

[1] CHEN W Q, ZHENG R S, BAADE P D, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[2] LIU J, YANG X L, ZHANG S W, et al. 中国口咽癌的发病率、死亡率和时间格局: 一项基于人群的研究[J]. 癌症, 2019, 38(6): 272-281.
[3] VOLPI C C, CINISELLI C M, GUALENI A V, et al. In situ hybridization detection methods for HPV16 E6/E7 mRNA in identifying transcriptionally active HPV infection of oropharyngeal carcinoma: an updating[J]. Hum Pathol, 2018, 74: 32-42.
[4] DE MARTEL C, PLUMMER M, VIGNAT J, et al. Worldwide burden of cancer attributable to HPV by site, country and HPV type[J]. Int J Cancer, 2017, 141(4): 664-670.
[5] TABERNA M, MENA M, PAVÓN M A, et al. Human papillomavirus-related oropharyngeal cancer[J]. Ann Oncol, 2017, 28(10): 2386-2398.
[6] CASTELLSAGUÉ X, ALEMANY L, QUER M, et al. HPV involvement in head and neck cancers: comprehensive assessment of biomarkers in 3680 patients[J]. J Natl Cancer Inst, 2016, 108(6): djv403.
[7] CHATURVEDI A K, ANDERSON W F, LORTET-TIEULENT J, et al. Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers[J]. J Clin Oncol, 2013, 31(36): 4550-4559.
[8] MENG H X, MIAO S S, CHEN K X, et al. Association of p16 as prognostic factors for oropharyngeal cancer: evaluation of p16 in 1470 patients for a 16 year study in northeast China[J]. Biomed Res Int, 2018, 2018: 9594568.
[9] LAM E W H, CHAN J Y W, CHAN A B W, et al. Prevalence, clinicopathological characteristics, and outcome of human papillomavirus-associated oropharyngeal cancer in southern Chinese patients[J]. Cancer Epidemiol Biomarkers Prev, 2016, 25(1): 165-173.
[10] EI-NAGGAR A K, CHAN J K C, GRANDIS J R, et a1. WHO classification of tumors of head and neck tumours[M]. 4th ed. Lyon: IARC Press, 2017: 1-347.
[11] CHERNOCK R D, EL-MOFTY S K, THORSTAD W L, et al. HPV-related nonkeratinizing squamous cell carcinoma of the oropharynx: utility of microscopic features in predicting patient outcome[J]. Head Neck Pathol, 2009, 3(3): 186-194.
[12] PAVER E C, CURRIE A M, GUPTA R, et al. Human Papilloma virus related squamous cell carcinomas of the head and neck: diagnosis, clinical implications and detection of HPV[J]. Pathology, 2020, 52(2): 179-191.
[13] LEWIS J S Jr, BEADLE B, BISHOP J A, et al. Human papillomavirus testing in head and neck carcinomas: guideline from the college of American pathologists[J]. Arch Pathol Lab Med, 2018, 142(5): 559-597.
[14] JALALY J B, HOSSEINI S M, SHAFIQUE K, et al. Current status of p16 immunohistochemistry and HPV testing in fine needle aspiration specimens of the head and neck[J]. Acta Cytol, 2020, 64(1/2): 30-39.
[15] XU S M, SUN B, ZHOU R, et al. Evaluation of p16 as a surrogate marker for transcriptionally active human papillomavirus status of oropharyngeal squamous cell carcinoma in an eastern Chinese population[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2020, 129(3): 236-245.e2.
[16] LU X, LIU K, PRISMAN E, et al. Prognostic value and cost benefit of HPV testing for oropharyngeal cancer patients[J]. Oral Dis, 2021: 2021Jun15.
[17] MARUR S, D'SOUZA G, WESTRA W H, et al. HPV-associated head and neck cancer: a virus-related cancer epidemic[J]. Lancet Oncol, 2010, 11(8): 781-789.
[18] NAUTA I H, RIETBERGEN M M, VAN BOKHOVEN A A J D, et al. Evaluation of the eighth TNM classification on p16-positive oropharyngeal squamous cell carcinomas in the Netherlands and the importance of additional HPV DNA testing[J]. Ann Oncol, 2018, 29(5): 1273-1279.
[19] BISHOP J A, LEWIS J S Jr, ROCCO J W, et al. HPV-related squamous cell carcinoma of the head and neck: an update on testing in routine pathology practice[J]. Semin Diagn Pathol, 2015, 32(5): 344-351.
[20] QUREISHI A, MAWBY T, FRASER L, et al. Current and future techniques for human Papilloma virus (HPV) testing in oropharyngeal squamous cell carcinoma[J]. Eur Arch Otorhinolaryngol, 2017, 274(7): 2675-2683.
[21] 杨志坚, 李忠佑, 朱月清, 等. 不同引物介导的聚合酶链反应检测人乳头瘤病毒DNA[J]. 中华实验和临床病毒学杂志, 1996, 10(3): 229- 232.
[22] BISHOP J A, MA X J, WANG H W, et al. Detection of transcriptionally active high- risk HPV in patients with head and neck squamous cell carcinoma as visualized by a novel E6/E7 mRNA in situ hybridization method[J]. Am J Surg Pathol, 2012, 36(12): 1874-1882.
[23] CRAIG S G, ANDERSON L A, MORAN M, et al. Comparison of molecular assays for HPV testing in oropharyngeal squamous cell carcinomas: a population- based study in northern Ireland[J]. Cancer Epidemiol Biomarkers Prev, 2020, 29(1): 31-38.
[24] VEYER D, WACK M, MANDAVIT M, et al. HPV circulating tumoral DNA quantification by droplet-based digital PCR: a promising predictive and prognostic biomarker for HPV-associated oropharyngeal cancers[J]. Int J Cancer, 2020, 147(4): 1222-1227.
[25] PRIGGE E S, ARBYN M, VON KNEBEL DOEBERITZ M, et al. Diagnostic accuracy of p16 INK4a immunohistochemistry in oropharyngeal squamous cell carcinomas: a systematic review and meta-analysis[J]. Int J Cancer, 2017, 140(5): 1186-1198.
[26] WONG K S, KRANE J F, JO V Y. Heterogeneity of p16 immunohistochemistry and increased sensitivity of RNA in situ hybridization in cytology specimens of HPV-related head and neck squamous cell carcinoma[J]. Cancer Cytopathol, 2019, 127(10): 632-642.
[27] ROOPER L M, GANDHI M, BISHOP J A, et al. RNA in situ hybridization is a practical and effective method for determining HPV status of oropharyngeal squamous cell carcinoma including discordant cases that are p16 positive by immunohistochemistry but HPV negative by DNA in situ hybridization[J]. Oral Oncol, 2016, 55: 11-16.
[28] YANG J Q, WU M, HAN F Y, et al. High risk HPV detection by RNAscope in situ hybridization combined with Cdc2 protein expression by immunohistochemistry for prognosis of oropharyngeal squamous cell carcinoma[J]. Int J Clin Exp Pathol, 2020, 13(8): 2192-2200.
[29] RANDÉN-BRADY R, CARPÉN T, JOUHI L, et al. In situ hybridization for high-risk HPV E6/E7 mRNA is a superior method for detecting transcriptionally active HPV in oropharyngeal cancer[J]. Hum Pathol, 2019, 90: 97-105.
[30] VENUTI A, PAOLINI F. HPV detection methods in head and neck cancer[J]. Head Neck Pathol, 2012, 6(Sup 1): S63-S74.
[31] HAEDICKE J, IFTNER T. A review of the clinical performance of the Aptima HPV assay[J]. J Clin Virol, 2016, 76(Suppl 1): S40-S48.
[32] HAN M, BERNADT C T, MURRAY B, et al. Aptima HR-HPV testing from Diff-Quick-stained fine-needle aspiration smears of oropharyngeal squamous cell carcinoma[J]. J Am Soc Cytopathol, 2016, 5(4): 221-226.
[33] KIR G, GUNEL H, OLGUN Z C, et al. High-risk human papillomavirus (HPV) detection in formalin-fixed paraffin- embedded cervical tissues: performances of Aptima HPV assay and Beckton Dickinson (BD) Onclarity assay[J]. J Clin Pathol, 2021: 207657.
[34] 郑歆, 陈晓品. 我国口咽癌与HPV的关系[J]. 国际肿瘤学杂志, 2020, 47(3): 164-168.